1. Healthcare

  2. •

    Biotechnology
OmniAb, Inc. Common Stock When Issued

OmniAb, Inc. Common Stock When Issued

OABIV
OmniAb, Inc. Common Stock When IssuedUS flagNASDAQ Global Market
6.50
USD
-0.20
- -
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChat
Sector
Healthcare
Industry
Biotechnology
Address
IPO Date
Oct 25, 2022
Similar Companies
Alector, Inc. (ALEC)
Notable Labs, Ltd. (NTBL)
Nicox S.A. (COX.PA)
Supriya Lifescience Limited (SUPRIYA.NS)
Kohjin Bio Co., Ltd. (177A.T)
POINT Biopharma Global Inc. (PNT)
Business
OmniAb, Inc. provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies through its proprietary OmniAb platform to enable discovery of next-generation therapeutics; the platform features transgenic animals including OmniRat, OmniChicken, and OmniMouse genetically modified to generate fully human antibody sequences; OmniFlic and OmniClic facilitate bispecific antibody discovery via common light chain approaches in rat and chicken hosts respectively; OmniTaur offers cow-inspired antibodies with unique structural attributes for complex targets; OmnidAb delivers heavy chain-only single-domain antibodies from a transgenic chicken host; and OmniDeep comprises in silico AI and machine learning tools integrated across discovery and optimization processes. OmniAb maintains core competencies in ion channel and transporter targets while supporting modalities such as bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, and targeted radiotherapeutics. The company, founded in 2012 and headquartered in Emeryville, California, operates primarily in the United States with over 100 active global partners across biopharmaceutical firms and research institutions. Recent developments include the launch of the xPloration Partner Access Program to enhance platform scalability and partner lab access; a $30 million private placement in August 2025 bolstering cash reserves to approximately $59.5 million as of September 30, 2025; new license agreements in 2025 with Incyte Corporation, Photinia Biosciences, A*Star, University of Leeds, Dana-Farber Cancer Institute, Orion Corporation, and VERAXA Biotech for bispecific antibody-drug conjugates; an asset sale to Angelini Pharma yielding a $3 million upfront payment with over $170 million in potential milestones; workforce reduction by 27 employees as part of cost-saving restructuring; and progression to 104 active partners, 399 programs, and 32 clinical or commercialized OmniAb-derived candidates as of late 2025.